Drug Trial Radar · NCT05396833
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Jun 7, 2022
Primary completion
Jul 14, 2026
Study completion Jul 14, 2026
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- May 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, clinical study conducted in multiple parts to establish the safety, tolerability, Pharmacokinetic/Pharmacodynamic (PK/PD) profile, maximum tolerated dose (MTD) combinations (if observed) and recommended dose for expansion (RDE) combination for tuvusertib in combination with lartesertib (in Part A1), food effect on the PK of lartesertib as monotherapy followed by treatment with tuvusertib in combination with lartesertib in participants with specific tumor types (in Part A1.1), relative bioavailability of a tuvusertib tablet formulation vs capsule formulation followed by treatment with tuvusertib (capsule) in combination with lartesertib in participants with specific tumor types (in Part A1.2), safety/tolerability and early signs of clinical activity of tuvusertib (capsule)and lartesertib in combination in participants with prostate cancer harboring loss of function (LoS) mutation in the gene ATM based on historic data collected prior to prescreening in circulating tumor (ct) DNA (liquid biopsies) or tumor biopsies (in Part A2), safety/tolerability and early signs of clinical activity of tuvusertib and lartesertib in combination in participants with endometrial cancer harboring LoS mutation(s) in the gene ARID1A based on historic data collected prior to prescreening in ctDNA (liquid biopsies) or tumor biopsies (in Part A3), the relative bioavailability of a tuvusertib tablet formulation (TF1, test) compared to a capsule formulation (reference) will also be investigated (in Part A2/A3), and identify a potential set of MTD combinations, and establish the RDE for the combination of tuvusertib and avelumab in participants with metastatic or locally advanced unresectable solid tumors (in Part B1).
Conditions
- Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions
TuvusertibDrug
Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
LartesertibDrug
Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
AvelumabDrug
Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A1: Number of Participants With Dose-Limiting Toxicities (DLTs) During the DLT Evaluation PeriodTime frame: Day 1 up to Day 28
- Part A1: Number of Participants With Adverse Events (AEs) and Treatment-Related AEsTime frame: Baseline up to 18 months
- Part B1: Number of Participants with Dose-Limiting Toxicities (DLTs) During the DLT Evaluation PeriodTime frame: Day 1 up to Day 28
- Part B1: Number of Participants with AEs and Treatment-Related AEsTime frame: Baseline up to 18 months
- Part A1: Change From Baseline in Pharmacodynamic (PD) BiomarkerTime frame: Pre-dose up to approximately 1 month
- Part B1: Change From Baseline in PD BiomarkerTime frame: Pre-dose up to approximately 1 month
- Part A1.1: PK Plasma Concentration of Lartesertib Under Fed and Fasted ConditionsTime frame: Day -1 up to Period 1 Day 1
- Part A2/A3: Objective Response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by InvestigatorTime frame: Up to 18 months after first dose administration
- Part A2/A3: Number of Participants With AEs and Treatment-Related AEsTime frame: Baseline up to 18 months
- Part A1.2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentTime frame: Day -4 up to Period 1 Day 1
- Part A1.2: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero to Last Quantifiable Concentration [Frel(AUC0-t)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentTime frame: Day -4 up to Period 1 Day 1
- Part A1.2: Ratio Maximum Observed Plasma Concentration (Ratio[Cmax]) of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentTime frame: Day -4 up to Period 1 Day 1
- Part A2/A3: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentTime frame: Day -4 up to Period 1 Day 1
- Part A2/A3: Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero to Last Quantifiable Concentration [Frel(AUC0-t)] of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentTime frame: Day -4 up to Period 1 Day 1
- Part A2/A3: Ratio Maximum Observed Plasma Concentration (Ratio[Cmax]) of Tuvusertib Test Treatment Compared to Tuvusertib Reference TreatmentTime frame: Day -4 up to Period 1 Day 1
Locations
22 sites in 5 countries. Site status is shown where the registry gives one.
Providence Medical Foundation
Santa Rosa, California
University of Miami School of Medicine
Miami, Florida
Augusta University - formerly Georgia Regents University
Augusta, Georgia
The University of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Mary Crowley Cancer Research Centers
Dallas, Texas
University of Texas M. D. Anderson Cancer Center - Partner
Houston, Texas
NEXT Oncology
San Antonio, Texas
Royal North Shore Hospital
St Leonards, Australia
Calvary Mater Newcastle - PARENT
Waratah, Australia
Princess Margaret Cancer Centre
Toronto, Canada
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Severance Hospital, Yonsei University Health System - Division of Infectious Diseases
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Hospital QuironSalud Barcelona - Next Oncology
Barcelona, Spain
Hospital Clinic de Barcelona - Servicio de Oncologia
Barcelona, Spain
Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica
Madrid, Spain
Hospital Universitario Quironsalud Madrid - NEXT Oncology
Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz - START Madrid FJD - Oncology Phase I
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.